Literature DB >> 12408496

Surveillance in Barrett's oesophagus: a critical reappraisal.

M E Craanen1, P Blok, G A Meijer, S G M Meuwissen.   

Abstract

BACKGROUND: Current recommendations are for endoscopic surveillance of patients with Barrett's oesophagus to detect dysplasia and to diagnose carcinoma at an early and possibly treatable stage. However, observations suggest that these current practice guidelines are thwarted by many factors often not taken into account. These observations stem from general surveillance aspects as well from specific data on Barrett's oesophagus. This review therefore aims at discussing data on the current surveillance strategy in conjunction with general surveillance aspects relevant for their interpretation.
METHODS: Literature survey of published articles.
RESULTS: A critical reappraisal of the literature shows that the current surveillance strategy is hampered by multiple problems with the marker dysplasia, cost-ineffectiveness, an overrated cancer risk and an astonishing lack of prospective, randomized data showing a clear benefit in terms of a greater life expectancy. Moreover, the decisive study is unlikely ever to be performed because of the large number of patients needed and the required length of follow-up. As a result, protocols are being carried out that have never been critically tested prior to large-scale clinical implementation.
CONCLUSIONS: Although these findings should not lead to therapeutic nihilism, the data raise the issue of whether or not surveillance protocols should be restricted to specialized referral centres with particular research efforts aimed at improving existing and developing new techniques that lack most of the described pitfalls and problems. Since it is foreseen that matters will not change rapidly in the (near) future, the clinician has no other choice than to rely on individually tailored arguments to survey taking into account for example family history, age and anxiety about potential long-term effects.

Entities:  

Mesh:

Year:  2002        PMID: 12408496     DOI: 10.1080/003655202320621373

Source DB:  PubMed          Journal:  Scand J Gastroenterol Suppl        ISSN: 0085-5928


  4 in total

1.  TP53 and progression from Barrett's metaplasia to oesophageal adenocarcinoma in a UK population cohort.

Authors:  L Murray; A Sedo; M Scott; D McManus; J M Sloan; L J Hardie; D Forman; C P Wild
Journal:  Gut       Date:  2006-05-08       Impact factor: 23.059

2.  MUC4 is increased in high grade intraepithelial neoplasia in Barrett's oesophagus and is associated with a proapoptotic Bax to Bcl-2 ratio.

Authors:  D A Bax; J Haringsma; A W C Einerhand; H van Dekken; P Blok; P D Siersema; E J Kuipers; J G Kusters
Journal:  J Clin Pathol       Date:  2004-12       Impact factor: 3.411

3.  A labelled discrete choice experiment adds realism to the choices presented: preferences for surveillance tests for Barrett esophagus.

Authors:  Michelle E Kruijshaar; Marie-Louise Essink-Bot; Bas Donkers; Caspar W N Looman; Peter D Siersema; Ewout W Steyerberg
Journal:  BMC Med Res Methodol       Date:  2009-05-19       Impact factor: 4.615

4.  Different perceptions of the burden of upper GI endoscopy: an empirical study in three patient groups.

Authors:  Marie-Louise Essink-Bot; Michelle E Kruijshaar; Dirk J Bac; Pieter J Wismans; Frank ter Borg; Ewout W Steyerberg; Peter D Siersema
Journal:  Qual Life Res       Date:  2007-07-17       Impact factor: 4.147

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.